{\rtf1\ansi\ansicpg1252\uc1 \deff0\deflang1033\deflangfe1033{\fonttbl{\f0\froman\fcharset0\fprq2{\*\panose 02020603050405020304}Times New Roman;}{\f1\fswiss\fcharset0\fprq2{\*\panose 020b0604020202020204}Arial;}
{\f32\froman\fcharset238\fprq2 Times New Roman CE;}{\f33\froman\fcharset204\fprq2 Times New Roman Cyr;}{\f35\froman\fcharset161\fprq2 Times New Roman Greek;}{\f36\froman\fcharset162\fprq2 Times New Roman Tur;}
{\f37\froman\fcharset177\fprq2 Times New Roman (Hebrew);}{\f38\froman\fcharset178\fprq2 Times New Roman (Arabic);}{\f39\froman\fcharset186\fprq2 Times New Roman Baltic;}{\f40\fswiss\fcharset238\fprq2 Arial CE;}{\f41\fswiss\fcharset204\fprq2 Arial Cyr;}
{\f43\fswiss\fcharset161\fprq2 Arial Greek;}{\f44\fswiss\fcharset162\fprq2 Arial Tur;}{\f45\fswiss\fcharset177\fprq2 Arial (Hebrew);}{\f46\fswiss\fcharset178\fprq2 Arial (Arabic);}{\f47\fswiss\fcharset186\fprq2 Arial Baltic;}}
{\colortbl;\red0\green0\blue0;\red0\green0\blue255;\red0\green255\blue255;\red0\green255\blue0;\red255\green0\blue255;\red255\green0\blue0;\red255\green255\blue0;\red255\green255\blue255;\red0\green0\blue128;\red0\green128\blue128;\red0\green128\blue0;
\red128\green0\blue128;\red128\green0\blue0;\red128\green128\blue0;\red128\green128\blue128;\red192\green192\blue192;}{\stylesheet{\ql \li0\ri0\widctlpar\aspalpha\aspnum\faauto\adjustright\rin0\lin0\itap0 
\fs24\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 \snext0 Normal;}{\*\cs10 \additive Default Paragraph Font;}}{\info{\author paulab}{\operator ericf}{\creatim\yr2019\mo4\dy30\hr16\min42}{\revtim\yr2019\mo4\dy30\hr17\min4}{\version3}{\edmins1}
{\nofpages2}{\nofwords360}{\nofchars2055}{\nofcharsws0}{\vern8247}}\margl720\margr648\margt2160\margb720 \widowctrl\ftnbj\aenddoc\noxlattoyen\expshrtn\noultrlspc\dntblnsbdb\nospaceforul\hyphcaps0\horzdoc\dghspace120\dgvspace120\dghorigin1701\dgvorigin1984
\dghshow0\dgvshow3\jcompress\viewkind1\viewscale100\nolnhtadjtbl \fet0\sectd \psz1\linex0\sectdefaultcl {\*\pnseclvl1\pnucrm\pnstart1\pnindent720\pnhang{\pntxta .}}{\*\pnseclvl2\pnucltr\pnstart1\pnindent720\pnhang{\pntxta .}}{\*\pnseclvl3
\pndec\pnstart1\pnindent720\pnhang{\pntxta .}}{\*\pnseclvl4\pnlcltr\pnstart1\pnindent720\pnhang{\pntxta )}}{\*\pnseclvl5\pndec\pnstart1\pnindent720\pnhang{\pntxtb (}{\pntxta )}}{\*\pnseclvl6\pnlcltr\pnstart1\pnindent720\pnhang{\pntxtb (}{\pntxta )}}
{\*\pnseclvl7\pnlcrm\pnstart1\pnindent720\pnhang{\pntxtb (}{\pntxta )}}{\*\pnseclvl8\pnlcltr\pnstart1\pnindent720\pnhang{\pntxtb (}{\pntxta )}}{\*\pnseclvl9\pnlcrm\pnstart1\pnindent720\pnhang{\pntxtb (}{\pntxta )}}\pard\plain \ql \li0\ri0\nowidctlpar
\tqc\tx5047\faauto\rin0\lin0\itap0 \fs24\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\f1\fs20 \tab }{\b\f1\fs28\ul\cf1 EVA-PCD FUNCTIONAL PROFILE}{\b\f1\fs34\ul\cf1 
\par }\pard \ql \li0\ri0\sb106\nowidctlpar\tx90\tx1500\tx6480\tx8640\faauto\rin0\lin0\itap0 {\b\f1\fs20\cf1 Patient:}{\f1\fs20 \tab }{\f1\fs20\cf1 Newcastle, Kimchi}{\f1\fs20 \tab }{\b\f1\fs20\cf1 Assay Date:}{\f1\fs20 \tab }{\f1\fs20\cf1 4/23/2019}{
\f1\fs25\cf1 
\par }\pard \ql \li0\ri0\sb139\nowidctlpar\tx90\tx1500\tx6480\tx8640\faauto\rin0\lin0\itap0 {\b\f1\fs20\cf1 Dx:}{\f1\fs20 \tab }{\f1\fs20\cf1 Squamous Cell Carcinoma}{\f1\fs20 \tab }{\b\f1\fs20\cf1 Assay Quality:}{\f1\fs20 \tab }{\f1\fs20\cf1 Good}{
\f1\fs25\cf1 
\par }{\b\f1\fs20\cf1 Prior Rx:}{\f1\fs20 \tab }{\f1\fs20\cf1 Treated}{\f1\fs20 \tab }{\b\f1\fs20\cf1 Report Date:}{\f1\fs20 \tab }{\f1\fs20\cf1 4/30/2019}{\f1\fs25\cf1 
\par }{\b\f1\fs20\cf1 Physician:}{\f1\fs20 \tab }{\f1\fs20\cf1 Dr. Yorb Newt}{\f1\fs20 \tab }{\b\f1\fs20\cf1 Specimen Number:}{\f1\fs20 \tab }{\f1\fs20\cf1 191123.02}{\f1\fs25\cf1 
\par }\pard \ql \li0\ri0\sb199\nowidctlpar\tqc\tx4680\faauto\rin0\lin0\itap0 {\f1\fs20 \tab }{\b\f1\fs28\cf1 SINGLE DRUG DOSE EFFECT ANALYSIS}{\b\f1\fs34\cf1 
\par }\pard \ql \li0\ri0\nowidctlpar\tx90\tx5040\tx6480\tx7200\faauto\rin0\lin0\itap0 {\b\f1\fs20\cf1 Drug}{\f1\fs20 \tab }{\b\f1\fs20\cf1 IC50}{\f1\fs20 \tab }{\b\f1\fs20\cf1 Units}{\f1\fs20 \tab }{\b\f1\fs20\cf1 Interpretation}{\b\f1\fs25\cf1 
\par }\pard \ql \li0\ri0\sb19\nowidctlpar\tx90\tx6480\faauto\rin0\lin0\itap0 {\f1\fs20\cf1 5-Fu}{\f1\fs20 \tab }{\f1\fs20\cf1 ug/ml}{\f1\fs25\cf1 
\par }{\f1\fs20\cf1 Cisplatin}{\f1\fs20 \tab }{\f1\fs20\cf1 ug/ml}{\f1\fs25\cf1 
\par }{\f1\fs20\cf1 Cisplatin & Gemcitabine}{\f1\fs20 \tab }{\f1\fs20\cf1 ug/ml}{\f1\fs25\cf1 
\par }{\f1\fs20\cf1 Gemcitabine}{\f1\fs20 \tab }{\f1\fs20\cf1 ug/ml}{\f1\fs25\cf1 
\par }{\f1\fs20\cf1 Irinotecan}{\f1\fs20 \tab }{\f1\fs20\cf1 ug/ml}{\f1\fs25\cf1 
\par }\pard \ql \li0\ri0\sb19\nowidctlpar\tx90\tx5040\tx6480\tx7200\faauto\rin0\lin0\itap0 {\f1\fs20\cf1 Taxol}{\f1\fs20 \tab }{\f1\fs20\cf1 3.1}{\f1\fs20 \tab }{\f1\fs20\cf1 ug/ml}{\f1\fs20 \tab }{\f1\fs20\cf1 Sensitive}{\f1\fs25\cf1 
\par }{\f1\fs20\cf1 Dichloroacetate}{\f1\fs20 \tab }{\f1\fs20\cf1 3.6}{\f1\fs20 \tab }{\f1\fs20\cf1 mg/ml}{\f1\fs20 \tab }{\f1\fs20\cf1 Intermediate}{\f1\fs25\cf1 
\par }{\f1\fs20\cf1 Bendamustine}{\f1\fs20 \tab }{\f1\fs20\cf1 >40}{\f1\fs20 \tab }{\f1\fs20\cf1 ug/ml}{\f1\fs20 \tab }{\f1\fs20\cf1 Resistant}{\f1\fs25\cf1 
\par }{\f1\fs20\cf1 Bortezomib (Proteasome)}{\f1\fs20 \tab }{\f1\fs20\cf1 0.02}{\f1\fs20 \tab }{\f1\fs20\cf1 ug/ml}{\f1\fs20 \tab }{\f1\fs20\cf1 Resistant}{\f1\fs25\cf1 
\par }{\f1\fs20\cf1 Cytoxan}{\f1\fs20 \tab }{\f1\fs20\cf1 4.2}{\f1\fs20 \tab }{\f1\fs20\cf1 ug/ml}{\f1\fs20 \tab }{\f1\fs20\cf1 Resistant}{\f1\fs25\cf1 
\par }{\f1\fs20\cf1 Imatinib (c-ABL/c-KIT/PDGFR)}{\f1\fs20 \tab }{\f1\fs20\cf1 36}{\f1\fs20 \tab }{\f1\fs20\cf1 ug/ml}{\f1\fs20 \tab }{\f1\fs20\cf1 Resistant}{\f1\fs25\cf1 
\par }{\f1\fs20\cf1 Phenformin (Mitochondrial)}{\f1\fs20 \tab }{\f1\fs20\cf1 >121}{\f1\fs20 \tab }{\f1\fs20\cf1 ug/ml}{\f1\fs20 \tab }{\f1\fs20\cf1 Resistant}{\f1\fs25\cf1 
\par }{\f1\fs20\cf1 Vinorelbine}{\f1\fs20 \tab }{\f1\fs20\cf1 >10}{\f1\fs20 \tab }{\f1\fs20\cf1 ug/ml}{\f1\fs20 \tab }{\f1\fs20\cf1 Resistant}{\f1\fs25\cf1 
\par }{\f1\fs20\cf1 Selumetinib (MEK)}{\f1\fs20 \tab }{\f1\fs20\cf1 9.9}{\f1\fs20 \tab }{\f1\fs20\cf1 ug/ml}{\f1\fs20 \tab }{\f1\fs20\cf1 Active}{\f1\fs25\cf1 
\par }{\f1\fs20\cf1 Crizotinib (ALK/MET/ROS)}{\f1\fs20 \tab }{\f1\fs20\cf1 1.8}{\f1\fs20 \tab }{\f1\fs20\cf1 ug/ml}{\f1\fs20 \tab }{\f1\fs20\cf1 Moderately Active}{\f1\fs25\cf1 
\par }{\f1\fs20\cf1 Everolimus (mTOR)}{\f1\fs20 \tab }{\f1\fs20\cf1 7.3}{\f1\fs20 \tab }{\f1\fs20\cf1 ug/ml}{\f1\fs20 \tab }{\f1\fs20\cf1 Moderately Active}{\f1\fs25\cf1 
\par }{\f1\fs20\cf1 Palbociclib (CDK4/6)}{\f1\fs20 \tab }{\f1\fs20\cf1 8.2}{\f1\fs20 \tab }{\f1\fs20\cf1 ug/ml}{\f1\fs20 \tab }{\f1\fs20\cf1 Moderately Active}{\f1\fs25\cf1 
\par }{\f1\fs20\cf1 Afatinib (HER 1,2,4)}{\f1\fs20 \tab }{\f1\fs20\cf1 5.2}{\f1\fs20 \tab }{\f1\fs20\cf1 ug/ml}{\f1\fs20 \tab }{\f1\fs20\cf1 Inactive}{\f1\fs25\cf1 
\par }{\f1\fs20\cf1 BCL-2 Inhibitor (Bcl-2)}{\f1\fs20 \tab }{\f1\fs20\cf1 >6.3}{\f1\fs20 \tab }{\f1\fs20\cf1 ug/ml}{\f1\fs20 \tab }{\f1\fs20\cf1 Inactive}{\f1\fs25\cf1 
\par }{\f1\fs20\cf1 Cabozantinib (VEGF)}{\f1\fs20 \tab }{\f1\fs20\cf1 341.}{\f1\fs20 \tab }{\f1\fs20\cf1 ng/ml}{\f1\fs20 \tab }{\f1\fs20\cf1 Inactive}{\f1\fs25\cf1 
\par }{\f1\fs20\cf1 COTI-2 (p53)}{\f1\fs20 \tab }{\f1\fs20\cf1 3.3}{\f1\fs20 \tab }{\f1\fs20\cf1 ug/ml}{\f1\fs20 \tab }{\f1\fs20\cf1 Inactive}{\f1\fs25\cf1 
\par }{\f1\fs20\cf1 Enasidenib (IDH2)}{\f1\fs20 \tab }{\f1\fs20\cf1 13}{\f1\fs20 \tab }{\f1\fs20\cf1 ug/ml}{\f1\fs20 \tab }{\f1\fs20\cf1 Inactive}{\f1\fs25\cf1 
\par }{\f1\fs20\cf1 Entrectinib (ALK, TrkA/B/C, ROS1)}{\f1\fs20 \tab }{\f1\fs20\cf1 4.0}{\f1\fs20 \tab }{\f1\fs20\cf1 ug/ml}{\f1\fs20 \tab }{\f1\fs20\cf1 Inactive}{\f1\fs25\cf1 
\par }{\f1\fs20\cf1 Gefitinib (EGFR)}{\f1\fs20 \tab }{\f1\fs20\cf1 8.2}{\f1\fs20 \tab }{\f1\fs20\cf1 ug/ml}{\f1\fs20 \tab }{\f1\fs20\cf1 Inactive}{\f1\fs25\cf1 
\par }{\f1\fs20\cf1 JQ1 (MYC)}{\f1\fs20 \tab }{\f1\fs20\cf1 23}{\f1\fs20 \tab }{\f1\fs20\cf1 ug/ml}{\f1\fs20 \tab }{\f1\fs20\cf1 Inactive}{\f1\fs25\cf1 
\par }{\f1\fs20\cf1 Olaparib (PARP)}{\f1\fs20 \tab }{\f1\fs20\cf1 >100}{\f1\fs20 \tab }{\f1\fs20\cf1 ug/ml}{\f1\fs20 \tab }{\f1\fs20\cf1 Inactive}{\f1\fs25\cf1 
\par }{\f1\fs20\cf1 Pazopanib (VEGF/PDGFR/c-KIT)}{\f1\fs20 \tab }{\f1\fs20\cf1 35}{\f1\fs20 \tab }{\f1\fs20\cf1 ug/ml}{\f1\fs20 \tab }{\f1\fs20\cf1 Inactive}{\f1\fs25\cf1 
\par }{\f1\fs20\cf1 Regorafenib (VEGF/c-KIT/RAF)}{\f1\fs20 \tab }{\f1\fs20\cf1 1.4}{\f1\fs20 \tab }{\f1\fs20\cf1 ng/ml}{\f1\fs20 \tab }{\f1\fs20\cf1 Inactive}{\f1\fs25\cf1 
\par }{\f1\fs20\cf1 Sorafenib (VEGF/RAF)}{\f1\fs20 \tab }{\f1\fs20\cf1 10}{\f1\fs20 \tab }{\f1\fs20\cf1 ug/ml}{\f1\fs20 \tab }{\f1\fs20\cf1 Inactive}{\f1\fs25\cf1 
\par }{\f1\fs20\cf1 Sunitinib (c-KIT/VEGF/FLT-3)}{\f1\fs20 \tab }{\f1\fs20\cf1 8.7}{\f1\fs20 \tab }{\f1\fs20\cf1 ug/ml}{\f1\fs20 \tab }{\f1\fs20\cf1 Inactive}{\f1\fs25\cf1 
\par }{\f1\fs20\cf1 Vandetanib (VEGF)}{\f1\fs20 \tab }{\f1\fs20\cf1 >10}{\f1\fs20 \tab }{\f1\fs20\cf1 ug/ml}{\f1\fs20 \tab }{\f1\fs20\cf1 Inactive}{\f1\fs25\cf1 
\par }\pard \ql \li0\ri0\sb79\nowidctlpar\tqc\tx5040\faauto\rin0\lin0\itap0 {\f1\fs20 \tab }{\b\f1\fs28\cf1 MULTIPLE DRUG DOSE EFFECT ANALYSIS}{\b\f1\fs34\cf1 
\par }\pard \ql \li0\ri0\nowidctlpar\tx90\tx3660\tx5040\tx6480\tx7200\tx8640\faauto\rin0\lin0\itap0 {\b\f1\fs20\cf1 Drug}{\f1\fs20 \tab }{\b\f1\fs20\cf1 Ratio}{\f1\fs20 \tab }{\b\f1\fs20\cf1 IC50}{\f1\fs20 \tab }{\b\f1\fs20\cf1 Units}{\f1\fs20 \tab }{
\b\f1\fs20\cf1 Interpretation}{\f1\fs20 \tab }{\b\f1\fs20\cf1 Synergy}{\b\f1\fs25\cf1 
\par }{\f1\fs20 \page }{\f1\fs20\cf1 Cisplatin & 5-Fu}{\f1\fs20 \tab }{\f1\fs20\cf1 6.6:100}{\f1\fs20 \tab }{\f1\fs20\cf1 32}{\f1\fs20 \tab }{\f1\fs20\cf1 ug/ml}{\f1\fs20 \tab }{\f1\fs20\cf1 Resistant}{\f1\fs20 \tab }{\f1\fs20\cf1 N/A}{\f1\fs25\cf1 
\par }{\f1\fs20\cf1 Cisplatin & Irinotecan}{\f1\fs20 \tab }{\f1\fs20\cf1 6.6:100}{\f1\fs20 \tab }{\f1\fs20\cf1 21}{\f1\fs20 \tab }{\f1\fs20\cf1 ug/ml}{\f1\fs20 \tab }{\f1\fs20\cf1 Resistant}{\f1\fs20 \tab }{\f1\fs20\cf1 N/A}{\f1\fs25\cf1 
\par }\pard \ql \li0\ri0\sb19\nowidctlpar\tx90\tx3660\tx5040\tx6480\tx7200\tx8640\faauto\rin0\lin0\itap0 {\f1\fs20\cf1 Cisplatin & Gemcitabine & 5-Fu}{\f1\fs20 \tab }{\f1\fs20\cf1 134:100}{\f1\fs20 \tab }{\f1\fs20\cf1 28}{\f1\fs20 \tab }{\f1\fs20\cf1 ug/ml}{
\f1\fs20 \tab }{\f1\fs20\cf1 Sensitive}{\f1\fs20 \tab }{\f1\fs20\cf1 N/A}{\f1\fs25\cf1 
\par }{\f1\fs20\cf1 Cisplatin & Gemcitabine & Irinotecan}{\f1\fs20 \tab }{\f1\fs20\cf1 134:100}{\f1\fs20 \tab }{\f1\fs20\cf1 27}{\f1\fs20 \tab }{\f1\fs20\cf1 ug/ml}{\f1\fs20 \tab }{\f1\fs20\cf1 Sensitive}{\f1\fs20 \tab }{\f1\fs20\cf1 N/A}{\f1\fs25\cf1 
\par }{\f1\fs20\cf1 Cytoxan & Gemcitabine}{\f1\fs20 \tab }{\f1\fs20\cf1 5.4:263}{\f1\fs20 \tab }{\f1\fs20\cf1 63}{\f1\fs20 \tab }{\f1\fs20\cf1 ug/ml}{\f1\fs20 \tab }{\f1\fs20\cf1 Resistant}{\f1\fs20 \tab }{\f1\fs20\cf1 N/A}{\f1\fs25\cf1 
\par }{\f1\fs20\cf1 Cytoxan & Irinotecan}{\f1\fs20 \tab }{\f1\fs20\cf1 5.4:100}{\f1\fs20 \tab }{\f1\fs20\cf1 47}{\f1\fs20 \tab }{\f1\fs20\cf1 ug/ml}{\f1\fs20 \tab }{\f1\fs20\cf1 Resistant}{\f1\fs20 \tab }{\f1\fs20\cf1 N/A}{\f1\fs25\cf1 
\par }\pard \ql \li0\ri0\sb139\nowidctlpar\tx90\faauto\rin0\lin0\itap0 {\b\f1\fs28\cf1 INTERPRETATION:}{\b\f1\fs34\cf1 
\par }\pard \ql \li0\ri0\nowidctlpar\tx90\faauto\rin0\lin0\itap0 {\f1\fs20\cf1 Laboratory results represent only one part of the overall determination of therapy for patients and do not }{\f1\fs25\cf1 
\par }{\f1\fs20\cf1 guarantee outcomes nor indicate the specific drugs that should be used in a particular patient.}{\f1\fs22\cf1 
\par 
\par }{\f1\fs20\cf1 * The following compounds serve as in vitro surrogates for their respective drug classes, e.g., Cytoxan: = }{\f1\fs22\cf1 
\par }{\f1\fs20\cf1 Cyclophosphamide, Ifosfamide, Melphalan, Chlorambucil and related mustard alkylators; Cisplatin: = }{\f1\fs22\cf1 
\par }{\f1\fs20\cf1 Carboplatin; Doxorubicin: = Daunorubicin and Idarubicin; Trimetrexate: = Methotrexate; 5Fu + Interferon: =}{\f1\fs22\cf1 
\par }\pard \ql \li0\ri0\sb170\nowidctlpar\tx90\faauto\rin0\lin0\itap0 {\b\f1\cf1 Ex Vivo best regimen (EVBR\'ae) would be }{\b\f1\fs29\cf1 
\par }\pard \ql \li0\ri0\sb1193\nowidctlpar\tx90\faauto\rin0\lin0\itap0 {\f1\cf1 Robert A. Nagourney, MD}{\f1\fs29\cf1 
\par }\pard \ql \li0\ri0\nowidctlpar\tx90\faauto\rin0\lin0\itap0 {\f1\cf1 Laboratory and Medical Director}{\f1\fs26\cf1 
\par }{\f1\cf1 Rational Therapeutics}{\f1\fs26\cf1 
\par }}